当地时间4月15日，Mural Oncology宣布终止其新型免疫疗法nemvaleukin的所有临床开发计划，并裁员90%。该决定是在对黑色素瘤II期ARTISTRY-6研究和铂耐药卵巢癌III期ARTISTRY-7研究数据进行评估后做出的。尽管这一壮举似乎相当反常，但Mural的股价却强劲上涨，收盘时飙升134%至4152.01万美元。

The layoffs come as the biotech industry struggles. The post Mass. biotech company cuts 90% of workforce appeared first on Boston.com.

Elevation Oncology has become the second biotech this week to face calls from an activist investor to wind down the company.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

The writing is on the wall at Mural Oncology. Responding to clinical data, the biotech is laying off 90% of its employees and ...

Other pharmaceutical and health care companies recently announced layoffs — including Bayer, Siemens, RWJBarnabas Health and Bristol Myers Squibb — as they struggled to integrate AI On March 11, ...

Boston and Dublin biotech Mural Oncology is laying off nearly all of its employees and ending clinical development of its IL-2 drug nemvaleukin alfa.

The pharmaceutical industry is one of the most scientifically innovative and competitive industries, particularly in oncology. As of 2018, there were over 1,100 cancer therapies in development ...

We recently published a list of the 13 Best Biotech Penny Stocks to Buy According to Hedge Funds. In this article, we are ...

BOSTON, April 08, 2025 (GLOBE NEWSWIRE) -- General Oncology, Inc ... Abid brings over 20 years of experience in the biotechnology sector with expertise in financial strategy and corporate ...

We recently published a list of 10 Hot Biotech Stocks Under $5. In this article, we are going to take a look at where Cardiff Oncology, Inc. (NASDAQ:CRDF) stands against other hot biotech stocks ...